Aclaris Therapeutics’ (ACRS) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Aclaris Therapeutics (NASDAQ:ACRS) in a research note released on Thursday,Benzinga reports. They currently have a $16.00 price target on the biotechnology company’s stock. HC Wainwright also issued estimates for Aclaris Therapeutics’ FY2026 earnings at ($0.52) EPS and FY2027 earnings at ($0.55) EPS.

A number of other analysts also recently issued reports on ACRS. Craig Hallum began coverage on Aclaris Therapeutics in a report on Friday, January 30th. They set a “buy” rating and a $10.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aclaris Therapeutics in a report on Monday, December 29th. Finally, Wall Street Zen lowered Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $9.80.

Aclaris Therapeutics Trading Down 1.3%

Shares of NASDAQ:ACRS opened at $3.69 on Thursday. Aclaris Therapeutics has a 52 week low of $1.05 and a 52 week high of $4.89. The company’s 50 day moving average is $3.41 and its two-hundred day moving average is $2.77. The company has a market cap of $445.01 million, a PE ratio of -6.96 and a beta of 0.88.

Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings data on Thursday, February 26th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.01). The firm had revenue of $1.30 million for the quarter, compared to analysts’ expectations of $2.07 million. Aclaris Therapeutics had a negative return on equity of 52.04% and a negative net margin of 829.58%. As a group, equities research analysts expect that Aclaris Therapeutics will post -0.82 EPS for the current year.

Hedge Funds Weigh In On Aclaris Therapeutics

Institutional investors have recently modified their holdings of the business. ProShare Advisors LLC acquired a new stake in Aclaris Therapeutics during the 2nd quarter worth $26,000. AXQ Capital LP acquired a new position in Aclaris Therapeutics in the third quarter valued at $27,000. Police & Firemen s Retirement System of New Jersey acquired a new position in Aclaris Therapeutics in the second quarter valued at $28,000. XTX Topco Ltd purchased a new stake in shares of Aclaris Therapeutics in the second quarter valued at about $34,000. Finally, R Squared Ltd purchased a new stake in shares of Aclaris Therapeutics in the fourth quarter valued at about $37,000. 98.34% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Aclaris Therapeutics

Here are the key news stories impacting Aclaris Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a “Buy” and raised several near‑term EPS forecasts and FY outlooks while setting a $16 price target — implying large upside from current levels; the shop trimmed projected losses for FY2026 (to about ($0.48)) and FY2027 (to ($0.50)) and nudged several quarterly estimates higher. This is a bullish analyst endorsement that could support the stock over the medium term. Aclaris Therapeutics (NASDAQ:ACRS) Earns Buy Rating from HC Wainwright
• Positive Sentiment: Aclaris will present new, previously unreleased data from its open‑label Phase 2a trial of ATI‑2138 (oral ITK/JAK3 inhibitor) at the AAD meeting — an upcoming clinical readout that could act as a near‑term catalyst if results are favorable for atopic dermatitis. Aclaris Announces Poster on Results from Phase 2a Trial of ATI-2138
• Neutral Sentiment: Reports show an anomalous short‑interest entry (0 shares / NaN change) for March — the published figure appears meaningless and does not signal a clear short‑squeeze or increased bearish positioning. Treat this data as inconclusive until corrected filings appear.
• Negative Sentiment: Company fundamentals remain challenging: consensus EPS is deeply negative (around ($0.82) full‑year), prior quarterly results showed an EPS and revenue miss and large negative margins — factors that keep downside risk elevated despite upbeat analyst commentary and upcoming clinical data.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.